CIK 0001658551 · Non-accelerated filer<br>Smaller reporting company
Amylyx Pharmaceuticals, Inc.
Sign in to watch- Ticker
- AMLX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 464600503
- Phone
- 617-682-0917
- Business address
- 55 CAMBRIDGE PARKWAY, SUITE 6W, CAMBRIDGE, MA, 02142
- 4 Option exercise Co-Chief Executive Officer acquired 63,690 shares (option exercise)
- 4 Open-market sale Co-Chief Executive Officer sold 18,589 shares at $3.20 ($59,429)
- 4 Open-market sale Co-Chief Executive Officer sold 18,589 shares at $3.20 ($59,414)
- 4 Open-market sale Chief Medical Officer sold 11,442 shares at $3.20 ($36,559)
- 4 Open-market sale Chief Legal Officer sold 8,709 shares at $3.20 ($27,840)
- 4 Option exercise Co-Chief Executive Officer acquired 1,857 shares (option exercise)
- 4 Option exercise Co-Chief Executive Officer acquired 34,449 shares (option exercise)
- 4 Open-market buy Chief Financial Officer bought 40,000 shares at $2.53 ($101,368)
- 4 Open-market buy Director bought 50,000 shares at $2.13 ($106,590)
- 4/A Option exercise Chief Financial Officer acquired 18,165 shares (option exercise)
- 4 Open-market buy Director bought 100,000 shares at $2.20 ($219,800)
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Open-market buy Director bought 5,000 shares at an average $1.89 ($9,436)
- 4 Planned sale Chief Legal Officer sold 10,455 shares at $1.88 ($19,654)
- 4 Grant or award Chief Financial Officer acquired 91,180 shares (grant or award)
- 4 Grant or award Co-Chief Executive Officer acquired 179,850 shares (grant or award)
Page 5 of 11 · 207 filings